Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The safety of autologous adipose derived SVF combined with the ACAM2000 (Vaccinia) vaccine in patients with advanced solid tumors

Next Previous
Trial Profile

The safety of autologous adipose derived SVF combined with the ACAM2000 (Vaccinia) vaccine in patients with advanced solid tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SI 001 (Primary) ; SI 001 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Calidi Biotherapeutics

    • Most Recent Events

    • 22 Jun 2020 According to a Calidi Biotherapeutics media release, data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting II, which will be held in virtual format June 22 through June 24, 2020, due to COVID-19 concerns.
    • 06 Nov 2018 According to a Calidi Biotherapeutics media release, data from this trial ( safety findings and post-treatment observations of oncolytic vaccinia virus combined with adipose stromal vascular fraction (SVF) cells in autologous settings) will be presented at the Society for Immunotherapy of Cancer (SITC) upcoming 33rd Annual Meeting (7-11 Nov 2018, Washington, D.C.).
    • 31 Oct 2018 Results of this trial published online on Calidi Biotherapeutics website.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top